NAFL
MCID: NNL005
MIFTS: 63

Non-Alcoholic Fatty Liver Disease (NAFL)

Categories: Cancer diseases, Liver diseases, Metabolic diseases

Aliases & Classifications for Non-Alcoholic Fatty Liver Disease

MalaCards integrated aliases for Non-Alcoholic Fatty Liver Disease:

Name: Non-Alcoholic Fatty Liver Disease 12 43 15 17
Nonalcoholic Fatty Liver Disease 43 36 15
Non-Alcoholic Fatty Liver 12 15 17
Steatosis 43 6 17
Nafld 12 43
Susceptibility to Nonalcoholic Fatty Liver Disease 6
Non-Alcoholic Steatohepatitis 43
Nonalcoholic Steatohepatitis 43
Fatty Liver 43
Nafl 12
Nash 43

Classifications:



External Ids:

Disease Ontology 12 DOID:0080208 DOID:0080546
KEGG 36 H01333

Summaries for Non-Alcoholic Fatty Liver Disease

MedlinePlus Genetics : 43 Non-alcoholic fatty liver disease (NAFLD) is a buildup of excessive fat in the liver that can lead to liver damage resembling the damage caused by alcohol abuse, but that occurs in people who do not drink heavily. The liver is a part of the digestive system that helps break down food, store energy, and remove waste products, including toxins. The liver normally contains some fat; an individual is considered to have a fatty liver (hepatic steatosis) if the liver contains more than 5 to 10 percent fat.The fat deposits in the liver associated with NAFLD usually cause no symptoms, although they may cause increased levels of liver enzymes that are detected in routine blood tests. Some affected individuals have abdominal pain or fatigue. During a physical examination, the liver may be found to be slightly enlarged.Between 7 and 30 percent of people with NAFLD develop inflammation of the liver (non-alcoholic steatohepatitis, also known as NASH), leading to liver damage. Minor damage to the liver can be repaired by the body. However, severe or long-term damage can lead to the replacement of normal liver tissue with scar tissue (fibrosis), resulting in irreversible liver disease (cirrhosis) that causes the liver to stop working properly. Signs and symptoms of cirrhosis, which get worse as fibrosis affects more of the liver, include fatigue, weakness, loss of appetite, weight loss, nausea, swelling (edema), and yellowing of the skin and whites of the eyes (jaundice). Scarring in the vein that carries blood into the liver from the other digestive organs (the portal vein) can lead to increased pressure in that blood vessel (portal hypertension), resulting in swollen blood vessels (varices) within the digestive system. Rupture of these varices can cause life-threatening bleeding.NAFLD and NASH are thought to account for many cases of cirrhosis that have no obvious underlying cause (cryptogenic cirrhosis); at least one-third of people with NASH eventually develop cirrhosis. People with NAFLD, NASH, and cirrhosis are also at increased risk of developing liver cancer (hepatocellular cancer).NAFLD is most common in middle-aged or older people, although younger people, including children, are also affected. It is often considered as part of a group of conditions known collectively as the metabolic syndrome; in addition to NAFLD, the metabolic syndrome includes obesity, type 2 diabetes or pre-diabetes (insulin resistance), high levels of fats (lipids) such as cholesterol and triglycerides in the blood, and high blood pressure (hypertension). However, a person with NAFLD may not have all or any of the other conditions that make up the metabolic syndrome, and individuals with some or all of those conditions may not have NAFLD.

MalaCards based summary : Non-Alcoholic Fatty Liver Disease, also known as nonalcoholic fatty liver disease, is related to non-alcoholic steatohepatitis and body mass index quantitative trait locus 11. An important gene associated with Non-Alcoholic Fatty Liver Disease is MIR122 (MicroRNA 122), and among its related pathways/superpathways are Non-alcoholic fatty liver disease and Glycerolipid metabolism. The drugs Milk thistle and Atorvastatin have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and heart.

Disease Ontology : 12 A fatty liver disease characterized by the storing of excess fat in liver cells which is not caused by heavy alcohol use.

KEGG : 36 It has been reported that those patients with nonalcoholic fatty liver disease (NAFLD) are probably more common in those individuals with metabolic syndrome, which includes obesity and type 2 diabetes mellitus. The spectrum of NAFLD ranges from simple steatosis to steatohepatitis with hepatic inflammation and fibrosis, known as nonalcoholic steatohepatitis (NASH). Of those with NASH, approximately 20% will go on to develop cirrhosis and hepatocellular carcinoma.

Related Diseases for Non-Alcoholic Fatty Liver Disease

Diseases related to Non-Alcoholic Fatty Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 925)
# Related Disease Score Top Affiliating Genes
1 non-alcoholic steatohepatitis 33.4 MIR34A MIR21 MIR122
2 body mass index quantitative trait locus 11 32.1 PRMT7 MIR34A MIR30A MIR27B MIR27A MIR22
3 hepatocellular carcinoma 31.4 MIR34A MIR30A MIR29C MIR27A MIR26A1 MIR22
4 overnutrition 31.3 MIR34A MIR30A MIR27B MIR27A MIR22 MIR21
5 arteries, anomalies of 31.2 MIR34A MIR33A MIR30A MIR29C MIR27B MIR27A
6 peripheral nervous system disease 31.0 MIR34A MIR27A MIR22 MIR21 MIR122
7 disease by infectious agent 30.9 MIR34A MIR30A MIR27B MIR27A MIR22 MIR21
8 inherited metabolic disorder 30.9 MIR34A MIR30A MIR21 MIR122
9 acquired metabolic disease 30.7 MIR34A MIR30A MIR27B MIR27A MIR22 MIR21
10 renal fibrosis 30.7 MIR29C MIR21 MIR200B MIR130A
11 skin carcinoma 30.6 MIR34A MIR30A MIR29C MIR21 MIR140
12 myeloma, multiple 30.5 MIR30A MIR27A MIR26A1 MIR21 MIR140
13 pulmonary fibrosis, idiopathic 30.5 MIR30A MIR21 MIR140 MIR130A
14 leukemia, acute lymphoblastic 30.4 MIR27B MIR27A MIR22 MIR21 MIR130A
15 lipid storage disease 30.4 MIR22 MIR21 MIR122
16 glucose metabolism disease 30.4 MIR30A MIR27A MIR22 MIR21 MIR140
17 gastric cancer 30.3 MIR34A MIR30A MIR29C MIR27B MIR27A MIR22
18 intestinal disease 30.3 MIR34A MIR30A MIR29C MIR27B MIR27A MIR26A1
19 bile duct adenocarcinoma 30.3 MIR30A MIR21 MIR140
20 lymphoma, hodgkin, classic 30.2 MIR30A MIR21 MIR200A MIR140
21 lymphoma, non-hodgkin, familial 30.2 MIR34A MIR30A MIR27A MIR21 MIR200B MIR140
22 cardiovascular system disease 30.1 MIR34A MIR30A MIR27A MIR21
23 kidney cancer 30.1 MIR29C MIR27A MIR21 MIR200B MIR122
24 muscular dystrophy, duchenne type 30.1 MIR34A MIR30A MIR29C MIR22 MIR21 MIR130A
25 ovarian disease 30.1 MIR30A MIR27A MIR22 MIR21 MIR200B MIR200A
26 connective tissue disease 30.1 MIR34A MIR30A MIR29C MIR27A MIR22 MIR21
27 esophageal cancer 30.0 MIR34A MIR30A MIR21 MIR200A MIR140 MIR10B
28 prostate disease 30.0 MIR34A MIR30A MIR27A MIR22 MIR21 MIR200B
29 breast cancer 29.9 PRMT7 MSR1 MIR34A MIR30A MIR29C MIR27A
30 lung cancer 29.9 MIR34A MIR33A MIR30A MIR29C MIR27B MIR27A
31 disease of mental health 29.8 MIR34A MIR30A MIR22 MIR21 MIR200A MIR140
32 pancreas disease 29.7 MIR34A MIR33A MIR30A MIR27B MIR27A MIR22
33 ovarian cancer 29.7 MIR34A MIR30A MIR29C MIR27A MIR22 MIR21
34 glioblastoma 29.6 MIR34A MIR21 MIR132 MIR130A MIR10B
35 gastrointestinal system disease 29.5 MIR34A MIR30A MIR29C MIR27B MIR27A MIR26A1
36 liver disease 11.9
37 fatty liver disease 11.9
38 fatty liver disease, nonalcoholic 1 11.9
39 long-chain 3-hydroxyacyl-coa dehydrogenase deficiency 11.7
40 fatty liver disease, nonalcoholic 2 11.4
41 hypertriglyceridemia, transient infantile 11.4
42 fibrosis of extraocular muscles, congenital, 1 11.3
43 lipid metabolism disorder 11.3
44 lipodystrophy, familial partial, type 2 11.2
45 type 2 diabetes mellitus 11.2
46 reye syndrome 11.2
47 diabetes mellitus 11.2
48 body mass index quantitative trait locus 9 11.1
49 body mass index quantitative trait locus 8 11.1
50 body mass index quantitative trait locus 4 11.1

Graphical network of the top 20 diseases related to Non-Alcoholic Fatty Liver Disease:



Diseases related to Non-Alcoholic Fatty Liver Disease

Symptoms & Phenotypes for Non-Alcoholic Fatty Liver Disease

Drugs & Therapeutics for Non-Alcoholic Fatty Liver Disease

Drugs for Non-Alcoholic Fatty Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 398)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Milk thistle Approved, Experimental, Investigational Phase 4 65666-07-1
2
Atorvastatin Approved Phase 4 134523-00-5 60823
3
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
4
Losartan Approved Phase 4 114798-26-4 3961
5
Amlodipine Approved Phase 4 88150-42-9 2162
6
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
7
Simvastatin Approved Phase 4 79902-63-9 54454
8
Glimepiride Approved Phase 4 93479-97-1 3476
9
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
10
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
11
Ezetimibe Approved Phase 4 163222-33-1 150311
12
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
13
Empagliflozin Approved Phase 4 864070-44-0
14
Liraglutide Approved Phase 4 204656-20-2 44147092
15
Insulin detemir Approved Phase 4 169148-63-4 5311023
16
Insulin aspart Approved Phase 4 116094-23-6 16132418
17
Rifampicin Approved Phase 4 13292-46-1 5458213 5381226
18
Gliclazide Approved Phase 4 21187-98-4 3475
19
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
20
Phentermine Approved, Illicit Phase 4 122-09-8 4771
21
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
22
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
23
tannic acid Approved Phase 4 1401-55-4
24
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
25
Polyestradiol phosphate Approved Phase 4 28014-46-2
26
Alogliptin Approved Phase 4 850649-61-5 11450633
27
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
28
Cetrorelix Approved, Investigational Phase 4 120287-85-6 16129715 25074887
29
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
30
Testosterone enanthate Approved Phase 4 315-37-7 9416
31
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
32
Testosterone Approved, Investigational Phase 4 58-22-0 6013
33
Methyltestosterone Approved Phase 4 58-18-4 6010
34
Tocopherol Approved, Investigational Phase 4 1406-66-2
35
Dulaglutide Approved, Investigational Phase 4 923950-08-7
36
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
37
Metformin Approved Phase 4 657-24-9 14219 4091
38
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
39
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
40
Insulin glargine Approved Phase 4 160337-95-1
41
Zinc Approved, Investigational Phase 4 7440-66-6 32051
42
Saxagliptin Approved Phase 4 361442-04-8 11243969
43
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
44
Ribavirin Approved Phase 4 36791-04-5 37542
45
Aminolevulinic acid Approved Phase 4 106-60-5 137
46
Methionine Approved, Nutraceutical Phase 4 63-68-3 6137
47
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
48
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
49
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 6433735 5283731
50
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985

Interventional clinical trials:

(show top 50) (show all 1098)
# Name Status NCT ID Phase Drugs
1 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
2 Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
3 A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
4 Pleiotropic Effects and Safety of Sodium Glucose Co-transporter 2 Inhibitor Versus Sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Unknown status NCT02649465 Phase 4 Tofogliflozin;Glimepiride
5 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
6 THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease Unknown status NCT01956825 Phase 4
7 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Fatty Liver Disease Prediabetic Mexican Patients Unknown status NCT02051842 Phase 4 Metadoxine
8 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Unknown status NCT02964715 Phase 4 Empagliflozin
9 An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
10 Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods Unknown status NCT02210715 Phase 4 Isentress.
11 Pilot Study to Assess the Antiviral Activity and Safety of Besifovir Dipivoxil 150mg and L-carnitine 660mg Compared to Tenofovir Alafenamide 25mg in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver Unknown status NCT03604016 Phase 4 Besifovir dipivoxil;L-carnitine;Tenofovir Alafenamide
12 Complex Imaging Assessment of Steatosis in Patients Under Treatment With Combination Silimarin, Phyllanthus Niruri and Choline Unknown status NCT02669641 Phase 4
13 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
14 Ultrasonographic Modification of Liver Steatosis and Visceral Fat Induced by Treatment With Losartan and Simvastatin in Hypertensive Normocholesterolemic Obese Patients Unknown status NCT00669435 Phase 4 Losartan + Simvastatin;Amlodipine + Simvastatin
15 Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
16 Double Blinded Randomised Trial Comparing Metformin Versus Placebo in NASH Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
17 Effects of Exenatide (Byetta®) on Biochemical and Histological Parameters of Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
18 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
19 NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
20 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
21 A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD) Completed NCT01006889 Phase 4 Exenatide
22 A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease Completed NCT03434613 Phase 4 Rosuvastatin;Rosuvastatin/ezetimibe combination
23 Clinical Study Evaluating the Efficacy and Safety of Montelukast in the Treatment of Non-Alcoholic Steatohepatitis (NASH) Completed NCT04537780 Phase 4 Montelukast
24 The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study Completed NCT03222206 Phase 4 Salsalate
25 Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM). Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
26 Comparison of Efficacy of Liraglutide, Metformin and Gliclazide MR on Hepatic Lipid Content in Patients With Type 2 Diabetes (T2DM) and Non-alcoholic Fatty Liver (NAFLD) Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
27 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
28 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
29 The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease Completed NCT00760513 Phase 4 OMACOR;Placebo oral capsule
30 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
31 Efficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
32 PXR-aktivaation Vaikutus Maksan Rasvoittumiseen Completed NCT02329405 Phase 4 Rifampicin;Placebo
33 Use of Vitamin D in Treatment of Non-Alcoholic Fatty Liver Disease Detected by Transient Elastography Completed NCT04038853 Phase 4 1,25-Dihydroxyvitamin D;Placebo
34 Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes Completed NCT02303730 Phase 4 Exenatide;insulin glargine
35 Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease:an Multicenter,Randomized, Double-blind, Parallel- Controlled Study. Completed NCT03796975 Phase 4 Combination of Pioglitazone and Metformin Tablets;Metformin Hydrochloride Tablets
36 Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes Completed NCT02637973 Phase 4 Empagliflozin;Placebo
37 Effectiveness and Tolerability of Phentermine in the Reduction of Intrahepatic Fat Infiltration, Adipose Tissue and Postoperative Complications in Patients Under Bariatric Surgery Completed NCT03849729 Phase 4 Phentermine
38 The Effect of Vitamin D Supplementation on the Glycemic Control and Non-alcoholic Fatty Liver Disease in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
39 A Multi-Centered, Prospective, Randomized, Placebo-Controlled Clinical Trial for the Treatment of Significant Steatosis or NASH With Xenical Followed by Treatment of Hepatitis C (HCV) With PEG-Interferon Alpha-2a/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
40 A 24 Week Monocentric Prospective Randomized, Placebo-controlled Trial to Evaluate Efficacy of Combination of Exenatide and Dapagliflozin Compared to Dapagliflozin and Placebo and Its Effects on Hepatic, Myocardial and Pancreatic Fat Distribution in Patients With Uncontrolled Type 2 Diabetes Mellitus. Completed NCT03007329 Phase 4 Exenatide;Exenatide matching Placebo;Dapagliflozin
41 Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among HIV/HCV-Coinfected Patients Receiving Two Nucleoside Analogs Plus Efavirenz: The Steral Study Completed NCT01900015 Phase 4 Raltegravir;Efavirenz
42 Biochemical and Echosonographic Impacts Using Siliphos-Selenium-Methionine-Alpha Lipoic Acid + Metformin Versus Metformin in Patients With Fatty Liver and Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
43 Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus Completed NCT01761318 Phase 4 Liraglutide;Liraglutide - Placebo
44 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin Completed NCT02102646 Phase 4 Triptorelin
45 Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus and South Asian Descent Completed NCT02660047 Phase 4 Liraglutide;Liraglutide - Placebo
46 Effect on Liver Fat, Adipose Tissue and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Once Daily Raltegravir in HIV+ Patients With Body Mass Index Over 25 kg/m2 and With at Least One Metabolic Syndrome Component Completed NCT03374358 Phase 4 Raltegravir
47 Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver Recruiting NCT03646292 Phase 4 Pioglitazone;Empagliflozin;Combination of pioglitazone and empagliflozin
48 To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes: A Prospective, Open-Label, Single-Arm, Single-Center Clinical Study Recruiting NCT03950505 Phase 4 Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks
49 Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial Recruiting NCT03198572 Phase 4 Placebo;Berberine
50 The Effect of Consecutive Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease (NAFLD) - a Randomized-controlled Trial - Recruiting NCT04465032 Phase 4

Search NIH Clinical Center for Non-Alcoholic Fatty Liver Disease

Genetic Tests for Non-Alcoholic Fatty Liver Disease

Anatomical Context for Non-Alcoholic Fatty Liver Disease

MalaCards organs/tissues related to Non-Alcoholic Fatty Liver Disease:

40
Liver, Kidney, Heart, Endothelial, Adipocyte, Thyroid, Ovary

Publications for Non-Alcoholic Fatty Liver Disease

Articles related to Non-Alcoholic Fatty Liver Disease:

(show top 50) (show all 28215)
# Title Authors PMID Year
1
Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease. 61 47
20497147 2010
2
Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD. 61 47
19780876 2010
3
Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. 47
20956972 2011
4
Diagnostic Efficacy of Serum Mac-2 Binding Protein Glycosylation Isomer and Other Markers for Liver Fibrosis in Non-Alcoholic Fatty Liver Diseases. 61
33303715 2021
5
Non-invasive Assessment of Liver Fat in ob/ob Mice Using Ultrasound-Induced Thermal Strain Imaging and Its Correlation with Hepatic Triglyceride Content. 61
33468357 2021
6
miR-125b promotes the NF-κB-mediated inflammatory response in NAFLD via directly targeting TNFAIP3. 61
33515562 2021
7
Exome-wide scan identifies significant association of rs4788084 in IL27 promoter with increase in hepatic fat content among Indians. 61
33444683 2021
8
Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis. 61
33490936 2021
9
Gut dysbiosis as a driver in alcohol-induced liver injury. 61
33598648 2021
10
Hepatic Ago2 Regulates PPARα for Oxidative Metabolism Linked to Glycemic Control in Obesity and Post Bariatric Surgery. 61
33567453 2021
11
Relation of computed tomography features of the pancreatic tissue and development of pancreatic fistula after pancreaticoduodenectomy. 61
33227614 2021
12
Functional foods from the tropics to relieve chronic normobaric hypoxia. 61
33333240 2021
13
The influence of PM2.5 exposure on non-alcoholic fatty liver disease. 61
33513397 2021
14
Non-alcoholic fatty liver disease does not increase dementia risk although histology data might improve risk prediction. 61
33554097 2021
15
Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model. 61
33482185 2021
16
Urantide decreases hepatic steatosis in rats with experimental atherosclerosis via the MAPK/Erk/JNK pathway. 61
33604686 2021
17
Extended-release naltrexone/bupropion and liver health: Pooled, post hoc analysis from four randomized controlled trials. 61
33275326 2021
18
Lactobacillus casei YRL577 ameliorates markers of non-alcoholic fatty liver and alters expression of genes within the intestinal bile acid pathway. 61
32718371 2021
19
Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis. 61
33342543 2021
20
Can Dasatinib Ameliorate the Hepatic changes, Induced by Long Term Western Diet, in Mice? 61
33144268 2021
21
Quercetin mitigates ethanol-induced hepatic steatosis in zebrafish via P2X7R-mediated PI3K/ Keap1/Nrf2 signaling pathway. 61
33186701 2021
22
Postnatal exposure to DINP was associated with greater alterations of lipidomic markers for hepatic steatosis than DEHP in postweaning mice. 61
33223173 2021
23
Clinical Feasibility of Quantitative Ultrasound Imaging for Suspected Hepatic Steatosis: Intra- and Inter-examiner Reliability and Correlation with Controlled Attenuation Parameter. 61
33277108 2021
24
Hepatoprotection by Ginsenoside Rg1 in alcoholic liver disease. 61
33412392 2021
25
Exercise suppresses NLRP3 inflammasome activation in mice with diet-induced NASH: a plausible role of adropin. 61
33268842 2021
26
NUPR1 protects liver from lipotoxic injury by improving the endoplasmic reticulum stress response. 61
33566371 2021
27
Visceral adipose tissue-directed FGF21 gene therapy improves metabolic and immune health in BTBR mice. 61
33575433 2021
28
Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression. 61
33275980 2021
29
Association between environmental exposure to cadmium and risk of suspected non-alcoholic fatty liver disease. 61
33220986 2021
30
Performance Characteristics, Intra- and Inter-operator Agreement of Transient Elastography in Pediatric Nonalcoholic Fatty Liver Disease. 61
33230078 2021
31
Characterization and hypoglycemic effects of sulfated polysaccharides derived from brown seaweed Undaria pinnatifida. 61
33038776 2021
32
Novel GYS2 mutations in a Japanese patient with glycogen storage disease type 0a. 61
33489759 2021
33
Mitophagy-mediated adipose inflammation contributes to type 2 diabetes with hepatic insulin resistance. 61
33315085 2021
34
Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: An analysis of the J-LINK study. 61
33236464 2021
35
Evaluation of the histological variability of core and wedge biopsies in nonalcoholic fatty liver disease in bariatric surgical patients. 61
32170564 2021
36
Sirtuin 6 ameliorates alcohol-induced liver injury by reducing endoplasmic reticulum stress in mice. 61
33516881 2021
37
Interleukin-2 receptor alpha as a biomarker for nonalcoholic fatty liver disease diagnosis. 61
33306598 2021
38
De-novo nonalcoholic fatty liver disease at 5 years after liver transplantation: prevalence and predictive factors. 61
32317584 2021
39
Effects of Alpha-2-HS-glycoprotein on cognitive and emotional assessment in prediabetic and diabetic subjects. 61
33445096 2021
40
CAP for the detection of hepatic steatosis in clinical practice. 61
33460568 2021
41
Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. 61
33460567 2021
42
Optimal thresholds for ultrasound attenuation parameter in the evaluation of hepatic steatosis severity: evidence from a cohort of patients with biopsy-proven fatty liver disease. 61
32398489 2021
43
Icaritin ameliorates hepatic steatosis via promoting fatty acid β-oxidation and insulin sensitivity. 61
33417961 2021
44
Impact of laparoscopic sleeve gastrectomy on fibrosis stage in patients with child-A NASH-related cirrhosis. 61
32152677 2021
45
Accuracy of controlled attenuation parameter compared with ultrasound for detecting hepatic steatosis in children with severe obesity. 61
32910234 2021
46
SR-BI deficiency disassociates obesity from hepatic steatosis and glucose intolerance development in high fat diet-fed mice. 61
33321184 2021
47
Sirtuin 6 supra-physiological overexpression in hypothalamic pro-opiomelanocortin neurons promotes obesity via the hypothalamus-adipose axis. 61
33583107 2021
48
Prediction, identification and progression of histopathological liver disease activity in children with intestinal failure. 61
33002568 2021
49
Double-lobectomy in a steatotic liver transplantation rat model. 61
33603863 2021
50
Intravoxel incoherent motion diffusion-weighted MRI for the characterization of inflammation in chronic liver disease. 61
32876833 2021

Variations for Non-Alcoholic Fatty Liver Disease

ClinVar genetic disease variations for Non-Alcoholic Fatty Liver Disease:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PRMT7 NM_019023.5(PRMT7):c.1713C>A (p.Cys571Ter) SNV Pathogenic 523434 rs1251713297 16:68389688-68389688 16:68355785-68355785
2 PRMT7 NM_019023.5(PRMT7):c.322G>T (p.Glu108Ter) SNV Pathogenic 523435 rs1014959895 16:68363008-68363008 16:68329105-68329105
3 PNPLA3 NM_025225.3(PNPLA3):c.*987_*989dup Duplication Uncertain significance 341961 rs3083314 22:44343239-44343240 22:43947359-43947360
4 PNPLA3 NM_025225.3(PNPLA3):c.*989dup Duplication Uncertain significance 341959 rs3083314 22:44343239-44343240 22:43947359-43947360
5 MT-TL1 NC_012920.1:m.3275C>T SNV Uncertain significance 370045 rs1057516057 MT:3275-3275 MT:3275-3275
6 OPA1 NM_001354663.2(OPA1):c.-260_-243del Deletion Uncertain significance 214916 rs863224140 3:193332587-193332604 3:193614798-193614815
7 PNPLA3 NM_025225.3(PNPLA3):c.*691_*692dup Duplication Likely benign 341954 rs397716964 22:44342941-44342942 22:43947061-43947062
8 PNPLA3 NM_025225.3(PNPLA3):c.*988_*989dup Duplication Likely benign 341960 rs3083314 22:44343239-44343240 22:43947359-43947360

Cosmic variations for Non-Alcoholic Fatty Liver Disease:

9 (show top 50) (show all 15626)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM97724722 ZXDB liver,NS,carcinoma,hepatocellular carcinoma c.1308C>A p.D436E 23:57593356-57593356 36
2 COSM94430614 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 36
3 COSM94436083 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 36
4 COSM94063771 ZSCAN20 liver,NS,carcinoma,hepatocellular carcinoma c.2314G>T p.G772W 1:33494658-33494658 36
5 COSM88264637 ZRSR2 liver,NS,carcinoma,hepatocellular carcinoma c.304G>T p.E102* 23:15803788-15803788 36
6 COSM102741209 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.859A>G p.M287V 22:29049340-29049340 36
7 COSM131494492 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.1159A>G p.M387V 22:29049340-29049340 36
8 COSM103081572 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.859A>G p.M287V 22:29049340-29049340 36
9 COSM95977701 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860= 20:49257501-49257501 36
10 COSM102131817 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860= 20:49257501-49257501 36
11 COSM95960776 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860= 20:49257501-49257501 36
12 COSM113317148 ZNF853 liver,NS,carcinoma,hepatocellular carcinoma c.1610G>T p.G537V 7:6622601-6622601 36
13 COSM99592496 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.829T>A p.F277I 19:36891962-36891962 36
14 COSM128686611 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.1072T>A p.F358I 19:36891962-36891962 36
15 COSM123358576 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.691C>T p.L231= 4:145885684-145885684 36
16 COSM123949383 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581= 4:145885684-145885684 36
17 COSM101741672 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581= 4:145885684-145885684 36
18 COSM86004822 ZNF653 liver,NS,carcinoma,hepatocellular carcinoma c.1553A>C p.H518P 19:11485673-11485673 36
19 COSM98561269 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 36
20 COSM142353152 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 36
21 COSM142221290 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 36
22 COSM99854658 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.156G>A p.V52= 19:52002156-52002156 36
23 COSM139729931 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 36
24 COSM141470046 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 36
25 COSM141819438 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 36
26 COSM145038099 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 36
27 COSM91868668 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.3900G>T p.K1300N 19:30557161-30557161 36
28 COSM91880764 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.2171-78T>G p.? 19:30534769-30534769 36
29 COSM140721836 ZNF521 liver,NS,carcinoma,hepatocellular carcinoma c.2998+205G>A p.? 18:25194955-25194955 36
30 COSM131506983 ZNF521 liver,NS,carcinoma,hepatocellular carcinoma c.3658+205G>A p.? 18:25194955-25194955 36
31 COSM94799980 ZNF521 liver,NS,carcinoma,hepatocellular carcinoma c.3658+205G>A p.? 18:25194955-25194955 36
32 COSM90582798 ZNF518B liver,NS,carcinoma,hepatocellular carcinoma c.1624G>T p.E542* 4:10444705-10444705 36
33 COSM87577038 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.6715G>T p.V2239L 9:106974156-106974156 36
34 COSM109096265 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.3433G>T p.V1145L 9:106974156-106974156 36
35 COSM104985080 ZNF385B liver,NS,carcinoma,hepatocellular carcinoma c.298+23785G>T p.? 2:179745718-179745718 36
36 COSM104427909 ZNF385B liver,NS,carcinoma,hepatocellular carcinoma c.20G>T p.S7I 2:179745718-179745718 36
37 COSM151538615 ZNF385B liver,NS,carcinoma,hepatocellular carcinoma c.253+23785G>T p.? 2:179745718-179745718 36
38 COSM127708351 ZNF345 liver,NS,carcinoma,hepatocellular carcinoma c.47-856A>T p.? 19:36891962-36891962 36
39 COSM135887725 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1168C>G p.L390V 16:89734008-89734008 36
40 COSM84511025 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1219C>G p.L407V 16:89734008-89734008 36
41 COSM111609487 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1444C>G p.L482V 16:89734008-89734008 36
42 COSM92353291 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.1010C>T p.T337I 12:133010889-133010889 36
43 COSM130415812 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.950C>T p.T317I 12:133010889-133010889 36
44 COSM88697750 ZNF217 liver,NS,carcinoma,hepatocellular carcinoma c.*194A>T p.? 20:53569094-53569094 36
45 COSM95253159 ZNF217 liver,NS,carcinoma,hepatocellular carcinoma c.*194A>T p.? 20:53569094-53569094 36
46 COSM94505616 ZMYND12 liver,NS,carcinoma,hepatocellular carcinoma c.425-1G>T p.? 1:42440026-42440026 36
47 COSM89943752 ZMYM4 liver,NS,carcinoma,hepatocellular carcinoma c.86-8201G>T p.? 1:35350724-35350724 36
48 COSM101398456 ZIC2 liver,NS,carcinoma,hepatocellular carcinoma c.-18C>T p.? 13:99982047-99982047 36
49 COSM113521587 ZGPAT liver,NS,carcinoma,hepatocellular carcinoma c.*197C>A p.? 20:63736116-63736116 36
50 COSM94679661 ZGPAT liver,NS,carcinoma,hepatocellular carcinoma c.*197C>A p.? 20:63736116-63736116 36

Expression for Non-Alcoholic Fatty Liver Disease

Search GEO for disease gene expression data for Non-Alcoholic Fatty Liver Disease.

Pathways for Non-Alcoholic Fatty Liver Disease

Pathways related to Non-Alcoholic Fatty Liver Disease according to KEGG:

36
# Name Kegg Source Accession
1 Non-alcoholic fatty liver disease hsa04932
2 Glycerolipid metabolism hsa00561

Pathways related to Non-Alcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.85 MIR34A MIR30A MIR29C MIR27B MIR27A MIR26A1
2 11.06 MIR30A MIR26A1 MIR132

GO Terms for Non-Alcoholic Fatty Liver Disease

Cellular components related to Non-Alcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.76 MIR34A MIR29C MIR27B MIR27A MIR22 MIR21
2 extracellular space GO:0005615 9.73 MIR30A MIR29C MIR27B MIR27A MIR26A1 MIR22
3 extracellular vesicle GO:1903561 9.32 MIR34A MIR30A MIR29C MIR27B MIR27A MIR26A1

Biological processes related to Non-Alcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.03 MIR34A MIR27B MIR21 MIR140 MIR132
2 negative regulation of cell migration GO:0030336 9.86 MIR34A MIR29C MIR26A1 MIR21
3 positive regulation of angiogenesis GO:0045766 9.85 MIR30A MIR27B MIR21 MIR132 MIR130A
4 negative regulation of angiogenesis GO:0016525 9.84 MIR34A MIR29C MIR21 MIR200B
5 transforming growth factor beta receptor signaling pathway GO:0007179 9.83 MIR30A MIR26A1 MIR21
6 cholesterol homeostasis GO:0042632 9.82 MIR34A MIR27B MIR132
7 negative regulation of NF-kappaB transcription factor activity GO:0032088 9.81 MIR27A MIR21 MIR140
8 negative regulation of tumor necrosis factor production GO:0032720 9.8 MIR140 MIR132 MIR130A
9 negative regulation of interleukin-6 production GO:0032715 9.79 MIR26A1 MIR140 MIR132
10 NIK/NF-kappaB signaling GO:0038061 9.78 MIR27B MIR27A MIR130A
11 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.77 MIR29C MIR26A1 MIR21
12 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.75 MIR29C MIR26A1 MIR22
13 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.73 MIR27B MIR27A MIR132 MIR10B
14 negative regulation of NIK/NF-kappaB signaling GO:1901223 9.72 MIR27B MIR21 MIR132
15 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.72 MIR27B MIR27A MIR26A1 MIR21 MIR130A
16 positive regulation of vascular endothelial cell proliferation GO:1905564 9.71 MIR27A MIR21 MIR132 MIR130A
17 miRNA mediated inhibition of translation GO:0035278 9.7 MIR29C MIR27B MIR27A MIR21 MIR200B MIR132
18 negative regulation of vascular endothelial cell proliferation GO:1905563 9.69 MIR34A MIR29C MIR132
19 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.67 MIR34A MIR21 MIR140
20 negative regulation of cholesterol efflux GO:0090370 9.67 MIR33A MIR27B MIR27A MIR26A1
21 positive regulation of cellular senescence GO:2000774 9.66 MIR34A MIR22
22 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.65 MIR27B MIR27A
23 positive regulation of lipid storage GO:0010884 9.65 MIR34A MIR10B
24 negative regulation of nitric-oxide synthase activity GO:0051001 9.65 MIR27B MIR26A1 MIR132
25 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.65 MIR27B MIR27A MIR21 MIR132 MIR10B
26 negative regulation of gene expression GO:0010629 9.65 MSR1 MIR34A MIR33A MIR29C MIR27B MIR27A
27 negative regulation of cell cycle G1/S phase transition GO:1902807 9.63 MIR29C MIR26A1
28 negative regulation of vascular wound healing GO:0061044 9.61 MIR34A MIR200B
29 positive regulation of smooth muscle cell differentiation GO:0051152 9.6 MIR34A MIR22
30 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.58 MIR27A MIR21
31 regulation of cholesterol esterification GO:0010872 9.57 MIR27B MIR27A
32 gene silencing by miRNA GO:0035195 9.53 MIR34A MIR33A MIR30A MIR29C MIR27B MIR27A
33 negative regulation of lipid binding GO:1900131 9.52 MIR27B MIR27A

Molecular functions related to Non-Alcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.65 MIR34A MIR30A MIR29C MIR27B MIR27A MIR21
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.5 MIR34A MIR33A MIR30A MIR29C MIR27B MIR27A

Sources for Non-Alcoholic Fatty Liver Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....